Skip to main content
SpringerLink
Log in

Ceftriaxone Alone or in Combination with Antibiotics in the Management of Infection in Cancer Patients

A Review of 41 Clinical Trials Involving 7350 Patient-Episodes

  • Clinical Review
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Empirical therapy with a broad-spectrum β-lactam and an aminoglycoside is the cornerstone of the management of patients with granulocytopenia and fever. These regimens are able to considerably lower mortality associated with serious infections; however, the optimal management of fever in these ‘difficult to treat’ patients remains controversial, with other factors such as cost-effectiveness becoming ever more important. The ideal antibiotic regimen for serious infections in cancer patients must therefore be effective in serious infections, but not be too expensive or inconvenient to use. This paper considers the evolution of this therapeutic intervention and reviews the opportunities available for once-daily therapy in treating infections associated with febrile neutropenia, with particular emphasis on the third generation cephalosporin, ceftriaxone. Ceftriaxone has highly favourable pharmacokinetics (half-life of 8 hours), which allow once-daily dosage regimens to be employed even in the most severe infections associated with cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bodey GP. Infection in cancer patients. A continuing association. Am J Med 1986; 81Suppl. A: 11–26

    Article  PubMed  CAS  Google Scholar 

  2. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–40

    PubMed  CAS  Google Scholar 

  3. Klastersky J, Zinner SH, Calandra T, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988; 24: 35–45

    Article  Google Scholar 

  4. Klasterky J. Empirical therapy for bacterial infections in granulocytopenic patients. Support Care Cancer 1994; 2: 161–8

    Article  Google Scholar 

  5. Cometta A, Glauser MP. The use of aminoglycosides in neutropenic patients. Schweiz Med Wochenschr 1996; 126Suppl. 76: 21S–27S

    Google Scholar 

  6. Viscoli C, Castagnola E. Factors predisposing cancer patients to infection. In: Klastersky J, editor. Infectious complications of cancer. Boston/Dordrecht/London: Kluwer Academic Publishers, 1995: 1–30

    Chapter  Google Scholar 

  7. The GIMEMA infection program. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: a randomised multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991; 115: 7–12

    Google Scholar 

  8. Menichetti F, Martino P, Bucaneve G and The Gimema Infection Program. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Antimicrob Agents Chemother 1994; 38: 2041–6

    Article  PubMed  CAS  Google Scholar 

  9. Raad IR, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992; 15: 197–210

    Article  PubMed  CAS  Google Scholar 

  10. Awada A, Van der Auwera P, Meunier F, et al. Streptococcal bacteremia in cancer patients. Clin Infect Dis 1992; 15: 33–48

    Article  PubMed  CAS  Google Scholar 

  11. Viscoli C, Wan Der Auwera P, Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother 1988; 21Suppl. C: 149–56

    PubMed  Google Scholar 

  12. Klastersky J. A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patients. Diagn Microbiol Dis 1989; 12Suppl. 4: 201S–207S

    Article  CAS  Google Scholar 

  13. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323–2

    Article  PubMed  CAS  Google Scholar 

  14. Del Favero A, Bucaneve G, Menichetti F. Empiric monotherapy in neutropenia: a realistic goal? Scand J Infect Dis 1995; 96: 34–7

    Google Scholar 

  15. Viscoli C, Bruzzi P, Glauser MP. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995; 31: 2013–22

    Article  Google Scholar 

  16. Pizzo PA, Hatorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–8

    Article  PubMed  CAS  Google Scholar 

  17. Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenemcilastatin as initial monotherapy for febrile granulocytopenic patients. Antimicrob Agents Chemother 1990; 34: 1336–41

    Article  PubMed  CAS  Google Scholar 

  18. EORTC-International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–93

    Google Scholar 

  19. Viscoli C, Dudley M, Ferrea G, et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991; 27Suppl. C: 113S–120S

    Google Scholar 

  20. Blaser J, Konig C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995; 14: 1029–38

    Article  PubMed  CAS  Google Scholar 

  21. Van der Auwera P, Klastersky J. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemotherapy 1987; 31: 1061–8

    Article  Google Scholar 

  22. Herbrecht R, Jehl F, Bergerat JP, et al. Etude de l’association ceftriaxone-netilmicine dans le traitement des infections chez les patients agranulocytaires. Med Malad Infect 1986; 8: 520–3

    Article  Google Scholar 

  23. Petrilli AS, de Camargo B, Bianchi A, et al. Ceftriaxone and amikacin in neutropenic children with infection. Medipress 1988; 4Suppl. 2: 36S–40S

    Google Scholar 

  24. Liu Y, Der Wang F. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients. Chemotherapy 1989; 35Suppl. 2: 16S–22S

    Article  Google Scholar 

  25. Cudillo L, Masi M, Scimò MT, et al. Ceftriaxone plus amikacin in a single daily dose as empiric therapy in granulocytopenic patients. J Chemother 1989; 6: 413–6

    Google Scholar 

  26. Martino P, Girmenia C, Raccah R, et al. Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients. Haematologica 1990; 75: 69–74

    PubMed  CAS  Google Scholar 

  27. Blanc C, Pollet JP, Bauters. Ceftriaxone plus amikacin in neutropenic patients: a report on 100 cases. Chemotherapy 1991; 37: 382–8

    Article  PubMed  CAS  Google Scholar 

  28. Emmerson AM, Lamport PA, Reeves DS, et al. The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics. Curr Med Res Opin 1985; 9: 480–93

    Article  PubMed  CAS  Google Scholar 

  29. Meunier F, Van der Auwera P, Aoun M, et al. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study. J Antimicrob Chemother 1991; 27Suppl. C: 129S–139S

    Google Scholar 

  30. Merry TL, Curtis H, Howden R, et al. Ceftriaxone as a single agent in empirical therapy of fever in children with agranulocytosis. Insights into the treatment of serious infections 1988; 1: 93–5

    Google Scholar 

  31. Bucaneve G, Menichetti F, Minotti V, et al. Comparison between ceftriaxone and imipenem/cilastatin as empiric monotherapy of infections in cancer patients. Chemotherapy 1989; 35Suppl. 2: 10S–15S

    Article  Google Scholar 

  32. Rolston KVI, Jones PG, Fainstein V, et al. Single agent therapy for infections in cancer patients: a prospective randomized trial comparing 3 extended-spectrum cephalosporins. Eur J Clin Microbiol Infect Dis 1991; 3: 139–45

    Article  Google Scholar 

  33. Petrilli AS, Melaragno R, Barros KVT, et al. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease. Pediatr Infect Dis J 1993; 12: 916–21

    Article  PubMed  CAS  Google Scholar 

  34. Oturai PS, Hollander NH, Hansen OP, et al. Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours. Eur J Cancer 1993; 9: 1274–9

    Article  Google Scholar 

  35. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128: 847–9

    Article  PubMed  CAS  Google Scholar 

  36. Karthaus M, Wolf HH, Kämpfe D, et al. Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. Chemotherapy 1998; 44: 343–54

    Article  PubMed  CAS  Google Scholar 

  37. Kern Wv for the International Antimicrobial Therapy Cooperative Group of the EORTC. Oral versus intravenous therapy for fever in cancer patients with an expected short duration of granulocytopenia. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, California. Washington DC: Amercian Society of Microbiology: 592-3

  38. Karthaus M, Egerer G, Kullmann KH, et al. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis 1998; 17: 501–4

    PubMed  CAS  Google Scholar 

  39. Bartolozzi S, Clerico A, Properzi E, et al. Ceftriaxone as a single agent in empirical therapy of unexplained fever in granulocytopenic children with solid tumors. J Chemother 1997; 9: 227–31

    PubMed  CAS  Google Scholar 

  40. Castagnola E, Lanino E, Giacchino R, et al. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer. J Chemother 1999; 11: 3–9

    Google Scholar 

  41. Pession A, Prete A, Paolucci G. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empiric management of febrile granulocytopenic children with cancer. Chemotherapy 1997; 43: 358–66

    Article  PubMed  CAS  Google Scholar 

  42. Fauser AA, Lang E, Kochling G, et al. A randomized clinical trial of ceftriaxone and teicoplanin versus ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow transplant recipients. Infection 1994; 4: 271–5

    Article  Google Scholar 

  43. Schmid L, Jeschko M, Wilder-Smith C, et al. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia. Chemotherapy 1991; 37: 346–52

    Article  PubMed  CAS  Google Scholar 

  44. Schaison GS, Decroly FC. Prophylaxis cost and effectiveness of therapy of infections caused by Gram-positive organisms in neutropenic children. J Antimicrob Chemother 1991; 27Suppl. B: 61S–67S

    Google Scholar 

  45. Charnas R, Ridolfi Luthi A, Ruch W (Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children). Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 1997; 16: 346–53

    Article  PubMed  CAS  Google Scholar 

  46. Rossini F, Pioltelli P, Bolis S, et al. Cost-effectiveness of ceftriaxone plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in patients with hematological malignancy and severe granulocytopenia. Clin Drug Invest 1998; 15: 425–33

    Article  CAS  Google Scholar 

  47. Yataganas X, Rombos Y, Vayopoulos G, et al. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/ amikacin as initial therapy of febrile episodes in neutropenic patients. Chemotherapy 1991; 37: 376–81

    Article  PubMed  CAS  Google Scholar 

  48. Au E, Ang PT. Management of chemotherapy-induced neutropenic sepsis — Combination of cephalosporin and aminoglycoside. Ann Acad Med 1993; 3: 319–22

    Google Scholar 

  49. Krcmèry V, Danisovicova A, Drgona L, et al. Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Neoplasma 1993; 2: 103–5

    Google Scholar 

  50. Leoni F, Ciolli S, Pascarella A, et al. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy 1993; 39: 147–52

    Article  PubMed  CAS  Google Scholar 

  51. Herbrecht R, Blaise D, Espinouse D, et al. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients. J Chemother 1995; 7Suppl. 2: 103S–110S

    Google Scholar 

  52. Smith L, Will AM, Williams RF, et al. Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children. J Infect 1990; 20: 201–206

    Article  PubMed  CAS  Google Scholar 

  53. Martino P, Girmenia C, Raccah R, et al. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992; 49: 49–52

    Article  PubMed  CAS  Google Scholar 

  54. Preis S, Jurgens H, Friedland C, et al. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children with cancer on an outpatient base. Klin Padiatr 1993; 205: 295–9

    Article  PubMed  CAS  Google Scholar 

  55. Yi Liu C, Der Wang F. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and Imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients. Chemotherapy 1989; 35Suppl. 2: 16–22

    Google Scholar 

  56. D’Antonio D, Fioritoni G, Iacone A, et al. Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empirical treatment of infections in patients with altered host defence: microbiological and clinical evaluation. Chemotherapy 1992; 38: 420–7

    Article  PubMed  Google Scholar 

  57. Krcmèry V, Koza I, Mardiak J, et al. Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients. Chemotherapy 1992; 38: 74–6

    Article  PubMed  Google Scholar 

  58. Bouffet E, Fuhrmann C, Frappaz D, et al. Once daily antibiotic regimen in paediatric oncology. Arch Dis Child 1994; 70: 484–7

    Article  PubMed  CAS  Google Scholar 

  59. Kaplinsky C, Drucker M, Goshen J, Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med sci 1994; 30: 649–51

    PubMed  CAS  Google Scholar 

  60. Menichetti F, Del Favero A, Bucaneve G, et al. Ceftriaxone versus aztreonam plus cefazolin for infections in cancer patients with adequate neutrophil count. Infection 1990; 18: 166–9

    Article  PubMed  CAS  Google Scholar 

  61. Sahu S, Bapna A, Pai SK, et al. Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Pediatr Hematol Oncol 1997; 14: 205–11

    Article  PubMed  CAS  Google Scholar 

  62. Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 1993; 58: 63–72

    PubMed  CAS  Google Scholar 

  63. Girmenia C, Moleti ML, Cartoni C, et al. Management of infective complications in patients with advanced hematologic malignancies in home care. Leukemia 1997; 11: 1807–12

    Article  PubMed  CAS  Google Scholar 

  64. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381–96

    Article  PubMed  CAS  Google Scholar 

  65. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148: 2561–8

    Article  PubMed  CAS  Google Scholar 

  66. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316–22

    PubMed  CAS  Google Scholar 

  67. Rubenstein EB, Rolston K. Outpatient management of febrile episodes in neutropenic cancer patients. Support Care Cancer 1994; 2: 369–73

    Article  PubMed  CAS  Google Scholar 

  68. Williams DN, Bosch D, Boots J, et al. Safety, efficacy, and cost-saving in an out-patient intravenous antibiotic program. Clin Ther 1993; 15: 169–79

    PubMed  CAS  Google Scholar 

  69. Poretz DM. Oupatient parenteral antibiotic therapy. Int J Antimicrob Agents 1995; 5: 9–12

    Article  PubMed  CAS  Google Scholar 

  70. Cometta A, Zinner S, De Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445–52

    Article  PubMed  CAS  Google Scholar 

  71. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108–15

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectivology Service, Department of Clinical Medicine, University ‘La Sapienza’, Viale dell’Università, 37, I00185, Rome, Italy

    M. Venditti

  2. Department of Cellular Biotechnology and Hematology, University ‘La Sapienza’, Rome, Italy

    P. Martino

  3. National Institute for Cancer Research, University of Genoa, Genoa, Italy

    C. Viscoli

  4. Department of Internal Medicine, Institute Jule Bordet, Brussels, Belgium

    J. Klastersky

Authors
  1. M. Venditti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Viscoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Klastersky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Venditti, M., Martino, P., Viscoli, C. et al. Ceftriaxone Alone or in Combination with Antibiotics in the Management of Infection in Cancer Patients. Clin. Drug Investig. 17, 195–210 (1999). https://doi.org/10.2165/00044011-199917030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199917030-00004

Keywords

Search

Navigation